Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NBI-1065890

Small molecule · developed by NEUROCRINE BIOSCIENCES

Phase 2 Most advanced trial
NBIX Developer
1 Registered trials

What is NBI-1065890?

NBI-1065890 is an investigational small-molecule drug studied in Tardive Dyskinesia.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
NEUROCRINE BIOSCIENCES (NBIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07365462 Phase 2 Tardive Dyskinesia Recruiting NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Tardive Dyskinesia

More from NEUROCRINE BIOSCIENCES

Crinecerfont FDA approved Valbenazine FDA approved Chronocort Phase 3 DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1070770 Phase 2 NBI-1117567 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Follow NBIX, the company behind NBI-1065890

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.